Abilify was initially developed by Otsuka Pharmaceutical and then later developed and brought to market by Bristol-Myers Squibb, one of America's foremost pharmaceutical companies. Containing the drug aripiprazole, Abilify is classed as an atypical antipsychotic and has been used clinically for the treatment of both schizophrenia and bipolar disorder. Later on, Abilify has also become to be used as an adjunctive treatment for patients with major depressive disorder, tic disorders and autism caused irritability. A partial dopamine agonist, Abilify's pharmacological properties are different from other atypical antipsychotics such as olanzapine or clozapine in that rather than acting as a pure antagonist of D2 dopamine receptors, Abilify displays selectivity of the D2 receptor while being a silent antagonist of sub-populations of some D2 receptors.
Abilify's unique properties means that for some patients it is the best antipsychotic for them. Its effects on not just dopamine receptors but on other neurochemicals is distinctive compared to other antipsychotic medicines. Furthermore, a Cochrane review established that Abilify caused fewer extrapyramidal symptoms compared to typical antipsychotics.
Abilify is used to treat those aged 15+ who suffer from a disease which displays symptoms such as hearing, seeing, and sensing things which are not really there as well as those who have delusional beliefs, incoherent speech and thought processes, and emotional and behaviour flatness such as bipolar and schizophrenia sufferers.
Abilify should be taken exactly as indicated by your doctor or pharmacist. In general, adults have a starting dose of 15mg taken once daily with a maximum suggested dose of 30mg a day. In adolescents the dose is usually smaller and increased gradually. Abilify should be taken at the same time each day and it does not matter whether it is taken with or without food. Always refer to product literature.